home / stock / iobt / iobt message board
Subject | By | Source | When |
---|---|---|---|
Good read | Work Harder | investorshub | 06/04/2023 4:16:10 PM |
good read | conix | investorshub | 06/04/2023 9:59:56 AM |
$IOBT Lets go go go go... Up up and away we go. | Phosphene | investorshub | 05/28/2023 8:00:56 AM |
$IOBT short squeeze | Phosphene | investorshub | 05/15/2023 8:37:05 AM |
IO Biotechs (NASDAQ:$IOBT ) lock-up period is set | Phosphene | investorshub | 05/03/2022 1:20:12 AM |
Bitoechs are waking up ---like they did last year. | conix | investorshub | 04/04/2022 8:17:37 PM |
IO Biotech Announces Third Clinical Collaboration with Merck | Phosphene | investorshub | 12/06/2021 2:34:29 PM |
What happened? IPO at $14/sh four weeks ago, | Eggplant | investorshub | 12/01/2021 7:15:12 PM |
I was right on the 7 | Work Harder | investorshub | 11/27/2021 6:29:38 AM |
Did Sunstone/Verland recoup initial seed? | Phosphene | investorshub | 11/22/2021 6:23:56 PM |
might wait till .035...lol | Staypositive1 | investorshub | 11/19/2021 8:56:30 PM |
IO Biotech begins trading on Nasdaq Global Market today. | Phosphene | investorshub | 11/05/2021 7:44:26 AM |
EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED | Phosphene | investorshub | 11/04/2021 6:55:51 PM |
Denmark's IO Biotech seeks $110M+ in Nasdaq debut. | Phosphene | investorshub | 11/04/2021 6:51:20 PM |
News, Short Squeeze, Breakout and More Instantly...
IO Biotech Inc. Company Name:
IOBT Stock Symbol:
NASDAQ Market:
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and ...
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with pembrolizumab still expected in Q3 2024; outcome of primary endp...